These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 29178102)

  • 1. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
    J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
    Feng Q; Zhao JR; Zhang AX; Li SL
    Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
    Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
    BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
    Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
    Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
    Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
    Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer.
    Okabe H; Tsunoda S; Hosogi H; Hisamori S; Tanaka E; Tanaka S; Sakai Y
    Ann Surg Oncol; 2015 Nov; 22(12):3954-61. PubMed ID: 25777087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
    Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
    World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.
    Abdallah EA; Braun AC; Flores BCTCP; Senda L; Urvanegia AC; Calsavara V; Fonseca de Jesus VH; Almeida MFA; Begnami MD; Coimbra FJF; da Costa WL; Nunes DN; Dias-Neto E; Chinen LTD
    Oncologist; 2019 Sep; 24(9):e854-e863. PubMed ID: 30846515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER.
    Junior PN; Neto RA; Forones NM
    Arq Gastroenterol; 2016; 53(2):62-7. PubMed ID: 27305410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.